May 22, 2018
Authored and Edited by Andrew Q. Leba
On March 14, 2018, FDA issued draft guidance on Pediatric HIV Infection: Drug Development for Treatment. The draft guidance provides general guidance on the development of drug products and clinical trial designs for treating pediatric HIV patients. This guidance does not address the full scope of considerations for drug development or clinical trial designs for treating adult or pediatric HIV patients.
The draft guidance identifies several major considerations for sponsors developing pediatric HIV drugs for global use. Regarding clinical trial designs, FDA recommends sponsors to: (1) include adolescents in its initial efficacy (phase III) trials or conduct a separate adolescent study in parallel with its adult phase III trials because dosing recommendations for antiretroviral drugs for adults and adolescents have been historically similar for the two groups, (2) base cohort enrollment and dose selections on weight-bands, predefined by the World Health Organization, rather than age during nonadolescent pediatric clinical studies, (3) enroll nonadolescent pediatric population cohorts within clinical studies in parallel rather than in series, unless the drug product in the studies warrants a different approach, and (4) use pharmacokinetic modeling using the adult and adolescent data for initial dose selection to initiate parallel enrollment of cohorts across the different weight groups in the nonadolescent pediatric population. Regarding drug development, FDA further advises sponsors to: (1) begin pediatric formulation development as soon as an adult dose is selected based on results from phase II trials, (2) obtain approval of new pediatric formulations by using comparable bioavailability/bioequivalence studies in adults, and (3) have early discussions with the WHO, FDA, and other organizations regarding facilitating drug development and meeting the needs of pediatric patients.
Readers are encouraged to read the draft guidance, also available on FDA’s website.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.